The current status of CAR T-cell therapy in CLL скачать в хорошем качестве

The current status of CAR T-cell therapy in CLL

In this video, Maria-Luisa Schubert, MD, MSc, Heidelberg University Hospital, Heidelberg, Germany, provides insight into the current status of CAR T-cell therapy in chronic lymphocytic leukemia (CLL), highlighting the need for cellular therapy in patients who have progressed following treatment with BTK inhibitors and BCL2 inhibitors. Dr Schubert notes that CD19 remains the primary target for CAR T-cell therapy in CLL, and that while efficacy has been observed, especially in patients with low tumor burden, manufacturing difficulties remain a significant challenge. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.